ARID1A and cancer: For example, investigation of the influence of the knockdown of 612 DNA-repair and cancer-relevant genes on the response to 31 chemotherapy compounds revealed that loss-of-function mutations in ARID1A and GPBP1 contribute to PARP inhibitor and platinum resistance in MCF10A, a non-tumorigenic human breast epithelial cell line [34].